Pomona, CA – According to filings with the U.S. Securities and Exchange Commission, LIPAC Oncology is raising $5,000,000.00 in new funding. Sources indicate as part of senior management President, Will Robberts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LIPAC Oncology

LIPAC Oncology is a clinical stage pharmaceutical company employing LiPax, its proprietary proliposomal intracavitary paclitaxel drug delivery platform, to enhance and reformulate proven cancer drugs into more effective treatments. LiPax, a locally delivered formulation of paclitaxel, is being developed for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC) and other intracavitary cancer indications. .

To learn more about LIPAC Oncology, visit http://www.lipaconcology.com/

Contact:
Will Robberts, President
909-595-0500
https://www.linkedin.com/in/willrobberts/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved